These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 31468473)

  • 1. Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
    Robertson K; Landay A; Miyahara S; Vecchio A; Masters MC; Brown TT; Taiwo BO
    J Neurovirol; 2020 Feb; 26(1):107-113. PubMed ID: 31468473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.
    Chan ES; Landay AL; Brown TT; Ribaudo HJ; Mirmonsef P; Ofotokun I; Weitzmann MN; Martinson J; Klingman KL; Eron JJ; Fichtenbaum CJ; Plants J; Taiwo BO
    AIDS; 2016 Aug; 30(13):2091-7. PubMed ID: 27281061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
    Robertson K; Maruff P; Ross LL; Wohl D; Small CB; Edelstein H; Shaefer MS
    J Neurovirol; 2019 Feb; 25(1):22-31. PubMed ID: 30298202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognition with maraviroc compared with tenofovir in HIV.
    Robertson KR; Miyahara S; Lee A; Brown TT; Chan ES; Berzins B; Rusin D; Eron JJ; Taiwo BO;
    AIDS; 2016 Sep; 30(15):2315-21. PubMed ID: 27333088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
    Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
    J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
    Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
    Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
    J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    Lazzaro A; Vai D; Barco A; Stroffolini G; Pirriatore V; Guastamacchia G; Nigra M; Ghisetti V; Tettoni MC; Noce G; Giaccone C; Trunfio M; Trentalange A; Bonora S; Di Perri G; Calcagno A
    J Acquir Immune Defic Syndr; 2024 Oct; 97(2):180-191. PubMed ID: 39250652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
    Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
    PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
    Stellbrink HJ; Le Fevre E; Carr A; Saag MS; Mukwaya G; Nozza S; Valluri SR; Vourvahis M; Rinehart AR; McFadyen L; Fichtenbaum C; Clark A; Craig C; Fang AF; Heera J
    AIDS; 2016 May; 30(8):1229-38. PubMed ID: 26854810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.
    Zanni MV; Toribio M; Robbins GK; Burdo TH; Lu MT; Ishai AE; Feldpausch MN; Martin A; Melbourne K; Triant VA; Suchindran S; Lee H; Hoffmann U; Williams KC; Tawakol A; Grinspoon SK
    JAMA Cardiol; 2016 Jul; 1(4):474-80. PubMed ID: 27438325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
    Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
    Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
    Becker A; Sifaoui F; Gagneux M; Desprez S; Vignoli P; Huguet D; Froidure M; Leduc D; Legout L
    Int J STD AIDS; 2015 Aug; 26(9):672-5. PubMed ID: 25179636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Moser C; Stein JH; Brown TT; Tran TT; Ribaudo HJ; Dube MP; Yang OO; Currier JS; McComsey GA
    J Infect Dis; 2016 Sep; 214(5):748-52. PubMed ID: 27354367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
    Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R
    AIDS; 2017 Jul; 31(11):1529-1534. PubMed ID: 28463882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation.
    Kousari A; Moser C; Olefsky M; Brown TT; Currier JS; McComsey GA; Scherzinger A; Stein JH; Lake JE; Erlandson KM
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):399-405. PubMed ID: 34326283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.